Rejoyn: FDA Cleared First Prescription Digital Therapeutic for MDD
On April 01, 2024: Otsuka and Click Therapeutics announced the FDA Clearance of Rejoyn™: the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms.
Watch our YouTube video, where Dr. Harvinder Singh has summarized Rejoyn in the following sections:
- Indication
- Product Description
- Recommended Treatment Schedule
- Alternate Treatment Schedule
- Mechanism of Action
- Clinical Trial Data: Mirai Trial
- Adverse Events: Suicidality
- How to Use/Prescribe?
WATCH DISCUSSION
JOIN EMAIL NEWSLETTER (FREE):
INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?
JOIN ACADEMY MEMBERSHIP:
This is a closed membership for medical professionals only.
- 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice.
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
- Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine.
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
- Goal: is to have all important clinically relevant topics in one place for ease of access.
DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.
Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com
© 2024 All Rights Reserved.
